Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antibodies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,074 result(s) found for: Antibodies. Displaying page 1 of 154.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005051-37 Sponsor Protocol Number: NL78705.018.21 Start Date*: 2021-12-06
    Sponsor Name:Amsterdam University Medical Centre
    Full Title: TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023976-16 Sponsor Protocol Number: Matab2 Start Date*: 2010-02-08
    Sponsor Name:University of Antwerp
    Full Title: Maternal antibodies against pertussis in neonates .
    Medical condition: Pertussis disease is reported in very young children who have not yet been (fully) vaccinated and did not receive sufficient maternal antibodies. Augmenting maternal antibody titers by administerin...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001304-15 Sponsor Protocol Number: AZGS2021005 Start Date*: 2021-05-06
    Sponsor Name:vzw az groeninge
    Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-...
    Medical condition: immuneresponse after vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000479-28 Sponsor Protocol Number: LTS13932 Start Date*: 2015-08-17
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
    Medical condition: Acute Myeloid Leukemia NOS
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001008-37 Sponsor Protocol Number: Bab1 Start Date*: 2005-11-01
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005581-19 Sponsor Protocol Number: 719_OPBG_2014 Start Date*: 2014-07-31
    Sponsor Name:Bambino Gesù Children’s Hospital
    Full Title: Immune memory to HPV induced by Gardasil in girls and boys
    Medical condition: Healthy subjects undergoing voluntary vaccination
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2021-000864-32 Sponsor Protocol Number: NL76798.078.21 Start Date*: 2021-03-29
    Sponsor Name:Erasmus MC
    Full Title: A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulines
    Medical condition: COVID-19 or protective effect against in B-cell depleted patients or vaccination non-responders
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000893-27 Sponsor Protocol Number: SJ2021016 Start Date*: 2021-04-27
    Sponsor Name:AZ Sint-Jan Brugge-Oostende AV
    Full Title: COVID-19: study to detect transfer of SARS-Cov-2 antibodies in breastmilk
    Medical condition: pregnancy lactating mothers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002530-17 Sponsor Protocol Number: D7220C00001 Start Date*: 2021-07-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD28...
    Medical condition: SARS-COV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002667-14 Sponsor Protocol Number: UHKT-RLP/2011 Start Date*: 2011-07-19
    Sponsor Name:Institute of Hematology and Blood Transfusion
    Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?
    Medical condition: Recurrent respiratory papillomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023849 Laryngeal papilloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-000572-41 Sponsor Protocol Number: LUC19-002 Start Date*: 2019-04-29
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced « cold » solid tumors
    Medical condition: Indication of treatment with anti-PD1 antibodies such as • Melanoma non BRAF mutated in first line of treatment • Melanoma BRAF mutated in first or second line of treatment • Lung cancer (NSCLC) in...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013284-19 Sponsor Protocol Number: HINABS-ITI Start Date*: 2009-12-10
    Sponsor Name:Medical University Innsbruck
    Full Title: Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta
    Medical condition: multiple sclerosis patients with neutralizing antibodies against interferon-beta
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002256-25 Sponsor Protocol Number: HYPATIA Start Date*: 2018-03-09
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies
    Medical condition: Pregnant women with antiphospholipid antibodies
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10048678 Antiphospholipid antibodies positive PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000035-23 Sponsor Protocol Number: VLA2001-307 Start Date*: 2022-04-11
    Sponsor Name:Valneva Austria GmbH
    Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI...
    Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000454-18 Sponsor Protocol Number: 110058 Start Date*: 2017-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedu...
    Medical condition: Healthy volunteers (Use of the candidate MMRV vaccine for immunization of healthy children 12 - 14 months of age against measles, mumps, rubella and varicella).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000627-24 Sponsor Protocol Number: 000134 Start Date*: 2014-06-26
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and s...
    Medical condition: Idiopathic growth hormone deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004969-14 Sponsor Protocol Number: 2111 Start Date*: 2014-01-28
    Sponsor Name:Heidi Mäkinen
    Full Title: Measurement of levels of infliximab and anti-infliximab antibodies in rheumatic patients
    Medical condition: rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10072736 Rheumatic disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001512-28 Sponsor Protocol Number: COVIM Start Date*: 2021-05-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations
    Medical condition: SARS-CoV-2 immunogenicity
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001357-31 Sponsor Protocol Number: IIV-478 Start Date*: 2021-05-03
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000461-33 Sponsor Protocol Number: P2020_312 Start Date*: 2021-02-17
    Sponsor Name:Hopital Erasme, Université Libre de Bruxelles
    Full Title: Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants
    Medical condition: Chronic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 14:56:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA